Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
646
datasets available to search
ShareScore release 0.7.1
Dataset results
646 results for “Pseudomonas aeruginosa”
Efectos de las mezclas del fármaco cloperidona y los antibióticos gentamicina/azitromicina sobre la formación de biopelícula de Pseudomonas aeruginosa
<p>Pseudomonas aeruginosa es una bacteria oportunista en infecciones nosocomiales, que tiene la capacidad de reducir la actividad de los antibióticos de amplio espectro debido a la formación de biopelícula, llevando a que sea categorizada como una bacteria de prioridad crítica a nivel mundial. La biopelícula está formada por comunidades de bacterias dentro de una matriz extracelular compuesta de proteínas, polisacáridos y ADN extracelular que le confieren protección, por ello se ha considerado como un blanco potencial para el control de P. aeruginosa. En este sentido, el objetivo del presente estudio fue evaluar el efecto de Cloperidona, Gentamicina y Azitromicina, así como de las mezclas binarias de Cloperidona/Gentamicina y Cloperidona/Azitromicina sobre la susceptibilidad y la formación de la biopelícula de P. aeruginosa (PAO1) ATCC BAA-47. Para lo cual, se determinó las concentraciones mínimas inhibitorias (CMI) por la técnica de microdilución para los compuestos y las dos mezclas, así como su efecto en la formación de biopelícula de P. aeruginosa por la técnica de tinción con cristal violeta. A partir de los resultados se determinó que las CMI para inhibir el crecimiento de P aeruginosa de los antibióticos gentamicina y azitromicina fueron de 1 y 31.25 µg/mL, respectivamente, mientras que Cloperidona no mostró efectos inhibitorios sobre el crecimiento a la máxima concentración evaluada de 100 µg/mL. Adicionalmente, para los compuestos, el mayor efecto en la formación de biopelícula a la menor concentración fue para Cloperidona a 0.39 µg/mL, gentamicina a 0.5 µg/mL y azitromicina a 1.95 µg/mL, con porcentajes de inhibición de 56%, 50% y 88%, respectivamente. Para las dos mezclas Cloperidona/Azitromicina y Cloperidona/Gentamicina (concentraciones sub-MIC) ninguna presentó mayores efectos inhibitorios si se compara con el efecto de la gentamicina cuando fue evaluada de manera independiente. Sin embargo, las mezclas Cloperidona/Gentamicina (0.39 µg/mL/ 0.03 µg/mL) y Cloperidona/Azitromicina (0.39 µg/mL/ 0.97 µg/mL) fueron las que mostraron el mayor efecto inhibitorio sobre la biopelícula con porcentajes de 77% y 88%, además de presentar efectos sinérgicos ya que fue posible bajar la concentración de los antibióticos en ambos casos para tener efectos inhibitorios en la formación de biopelícula. Estos resultados permiten concluir que las mezclas de los antibióticos con Cloperidona pueden ser utilizados para la reducción en la formación de la biopelícula, uno de los principales mecanismos que utiliza la bacteria para reducir la acciones de los antibióticos y así ser considerado como estrategia para frenar la resistencia microbiana.</p>
Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
ClinicalTrials.gov study NCT01315678. IPD Sharing: Not stated. Countries: 18. Publications: 1.
Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa
ClinicalTrials.gov study NCT00638365. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa
ClinicalTrials.gov study NCT00757237. IPD Sharing: Not stated. Countries: 13. Publications: 1.
Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects
ClinicalTrials.gov study NCT02696902. IPD Sharing: Not stated. Countries: 14. Publications: 1.
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
ClinicalTrials.gov study NCT01316276. IPD Sharing: Not stated. Countries: 17. Publications: 1.
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
ClinicalTrials.gov study NCT01641822. IPD Sharing: Not stated. Countries: 1. Publications: 1.
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
ClinicalTrials.gov study NCT02054156. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
ClinicalTrials.gov study NCT00558844. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
ClinicalTrials.gov study NCT04673175. IPD Sharing: NO. Countries: 1. Publications: 7.
Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria
ClinicalTrials.gov study NCT03219164. IPD Sharing: YES. Countries: 12. Publications: 1.
Data from: Life in the cystic fibrosis upper respiratory tract influences competitive ability of the opportunistic pathogen Pseudomonas aeruginosa
Open the record for dataset details and reuse information.
Aztreonam-induced filamentation in Pseudomonas aeruginosa
Open the record for dataset details and reuse information.
Ecology drives the evolution of diverse social strategies in Pseudomonas aeruginosa
Open the record for dataset details and reuse information.
Heterogenous susceptibility to R-pyocins in populations of Pseudomonas aeruginosa sourced from cystic fibrosis lungs
Open the record for dataset details and reuse information.
Experimental data for Pseudomonas aeruginosa from experimental evolution under different bottleneck sizes and antibiotic selection pressures
Open the record for dataset details and reuse information.
DNA Methyltransferase regulates nitric oxide homeostasis and virulence in a chronically adapted Pseudomonas aeruginosa strain
Open the record for dataset details and reuse information.
Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis
Open the record for dataset details and reuse information.
High prevalence of lipopolysaccharide mutants and R2-Pyocin susceptible variants in Pseudomonas aeruginosa populations sourced from cystic fibrosis lung infections
Open the record for dataset details and reuse information.
The evolution of virulence in Pseudomonas aeruginosa during chronic wound infection
<p>Opportunistic pathogens are associated with a number of chronic human infections, yet the evolution of virulence in these organisms during chronic infection remains poorly understood. Here, we tested the evolution of virulence in the human opportunistic pathogen Pseudomonas aeruginosa in a murine chronic wound model using a two-part serial passage and sepsis experiment, and found that virulence evolved in different directions in each line of evolution. We also assessed P. aeruginosa adaptation to a chronic wound after 42 days of evolution and found that morphological diversity in our evolved populations was limited compared to that previously described in cystic fibrosis (CF) infections. Using whole-genome sequencing, we found that genes previously implicated in P. aeruginosa pathogenesis (lasR, pilR, fleQ, rpoN and pvcA), contained mutations during the course of evolution in wounds, with selection occurring in parallel across all lines of evolution. Our findings highlight that (i) P. aeruginosa heterogeneity may be less extensive in chronic wounds than in CF lungs; (ii) genes involved in P. aeruginosa pathogenesis acquire mutations during chronic wound infection; (iii) similar genetic adaptations are employed by P. aeruginosa across multiple infection environments and (iv) current models of virulence may not adequately explain the diverging evolutionary trajectories observed in an opportunistic pathogen during chronic wound infection.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.